NCT06265350View on ClinicalTrials.gov

Cryoablation Combined With Cardonilizumab and Bevacizumab in Hepatocellular Carcinoma With Pulmonary Metastases

NARecruitingINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

February 2, 2024

Primary Completion Date

January 30, 2026

Study Completion Date

January 30, 2027

Conditions
Hepatocellular CarcinomaLiver Cancer Stage IVPulmonary MetastasesCadonilimabBevacizumabCryoablation
Interventions
DRUG

Cadonilimab

Cadonilimab, 375mg，Q3W， IV

DRUG

Bevacizumab

Bevacizumab, 7.5mg/kg，Q3W， IV

PROCEDURE

Cryoablation

Patients accepted Cryoablation of pulmanary metastases

Trial Locations (2)

510000

RECRUITING

Sun Yat-sen University Cancer Center, Guanzhou

RECRUITING

Sun Yat-sen University Cancer Center, Guanzhou

All Listed Sponsors
lead

Sun Yat-sen University

OTHER